A Study of Dideoxycytidine in HIV-Infected Patients
Status:
Completed
Trial end date:
1988-12-01
Target enrollment:
Participant gender:
Summary
To determine how much of a dose is absorbed by the body when zalcitabine ( dideoxycytidine;
ddC ) is given orally and how long the drug stays in the body after absorption or intravenous
(IV) administration.
Laboratory tests have shown that ddC is effective in stopping the growth of the HIV in test
tubes. The study will reveal the pharmacokinetic (blood levels) properties of this new drug
and how long the drug remains in the body at each of six doses. This should be useful
background information and should allow a simple and efficient comparative study of any new
oral formulation, such as a tablet or capsule, since dose-related problems will already be
known.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)